Product portfolio Leverage Adamis’ FDA approved SYMJEPI and ZIMHI products to target emergency treatment and overdose response channels, including hospitals, urgent care, EMS, and addiction treatment centers, as well as partnerships with health systems focused on rapid response to anaphylaxis and opioid overdose.

Expansion momentum Capitalize on recent merger activity and leadership changes to position as a growth partner for healthcare distributors and specialty pharma distributors seeking a broadened product line, leveraging DMK collaboration and committed financing to support expanded sales and marketing efforts.

Funding runway Target opportunities tied to the company’s public financing activity and ongoing clinical development for COVID-19 therapy Tem po l, offering services around market access, regulatory strategy, and payer engagement to accelerate adoption and reimbursement.

Operational scale With a lean team and notable revenue under $10 million, identify partnerships with contract sales organizations, patient education programs, and digital healthcare platforms to extend reach in allergy, respiratory, and inflammatory indications.

Technology leverage Support digital presence and operations via Adamis’ tech stack through managed hosting, cloud services, and security tooling to enable faster go-to-market for new products, telehealth integrations, and data-driven sales analytics for field teams.